Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $59

Cantor Fitzgerald analyst Carter Gould maintains Bristol-Myers Squibb (NYSE:BMY) with a Neutral and raises the price target from $54 to $59.